ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2311

Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2178

Online Education Significantly Improved Rheumatologists’ Knowledge of the Diagnosis and Management of Sjögren’s Disease

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1894

Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1938

Optimizing Patient Outcomes: The Experience of a Multidisciplinary Rheumatology and Hand Surgery Clinic with Point-of-Care Musculoskeletal Ultrasound Integration

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2157

Optimizing the Diagnosis and Treatment of Kawasaki Disease-Associated Macrophage Activation Syndrome: A Clinical Cohort and Literature Analysis

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-10:45AM: Abstract Number: 1730

Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

10:30AM-12:30PM: Abstract Number: 1928

Oral Health in Patients with Rheumatic Diseases: A Pilot Quality Improvement Program

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2418

ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2058

Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2104

Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2065

Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2261

Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1870

Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1803

Patching of Damaged Meniscus and Cartilage of Osteoarthritic Animals by MM-II, a Dispersion of Empty Large Multilamellar Liposomes

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2449

Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].